{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T07:12:07Z","timestamp":1695107527679},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:p>We successfully used a haploidentical transplantation protocol with posttransplant cyclophosphamide (CY) (50\u2009mg\/kg\/d on days +3 and +4) for in vivo T-cell depletion in patients with mucopolysaccharidosis using reduced-intensive conditioning regimens, followed by a busulfan-based conditioning regimen, which included busulfan (12 to 16\u2009mg\/kg) and fludarabine(150 to 200\u2009mg\/m<jats:sup>2<\/jats:sup>)+rabbit antihuman thymocyte globulin (7.5 to 10\u2009mg\/kg) as a conditioning regimen. Cyclosporine or tacrolimus, methotrexate, mycophenolate mofetil, and methylprednisolone were administered to prevent graft-versus-host disease (GVHD). After follow-up for a median period of 1.5 years, all 8 patients without preexisting severe comorbidities and early transplant referrals are alive, with 100% donor chimerism and excellent performance status. Only 1 patient developed chronic GVHD(II). We conclude that posttransplant CY is effective in vivo for T-cell depletion to promote full donor engraftment in patients with mucopolysaccharidosis. In addition, with posttransplant CY, the procedure reduced the rate of GVHD and the cost of transplant and improved the patients\u2019 quality of life.<\/jats:p>","DOI":"10.1097\/mph.0000000000001157","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T16:17:18Z","timestamp":1522858638000},"page":"e350-e354","source":"Crossref","is-referenced-by-count":2,"title":["Posttransplant Cyclophosphamide for HLA-haploidentical Transplantation in Patients With Mucopolysaccharidosis"],"prefix":"10.1097","volume":"40","author":[{"given":"Yan","family":"Yue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeliang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunqiao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/nm1201-1356","article-title":"Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment","volume":"7","author":"Priller","year":"2001","journal-title":"Nat Med"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s10545-005-0112-z","article-title":"Cumula- tive incidence rates of the mucopolysaccharidoses in Germany","volume":"28","author":"Baehner","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10545-012-9563-1","article-title":"Anaesthesia and airway management in mucopolysaccharidosis","volume":"36","author":"Walker","year":"2013","journal-title":"J Inherit Metab"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/ppul.22629","article-title":"Bronchoscopy and airway management in patients with mucopolysaccharidoses (MPS)","volume":"48","author":"Muhlebach","year":"2013","journal-title":"Pediatr Pulmonol"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.bbmt.2016.08.015","article-title":"Allogeneic hematopoietic stem cell transplantation in thirty-four pediatric cases of mucopolysaccharidosis\u2014a ten-year report from the China Children Transplant Group","volume":"22","author":"Wang","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclo- phosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bmt.2008.203","article-title":"Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases","volume":"42","author":"Brodsky","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2141.1980.tb07179.x","article-title":"In vitro effect of cyclopho- sphamide metabolites on chromosomes of Fanconi anaemia patients","volume":"45","author":"Berger","year":"1980","journal-title":"Br J Haematol"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Non- myeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O\u2019Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","article-title":"High- dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease","volume":"115","author":"Luznik","year":"2010","journal-title":"Blood"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/clinchem\/35.7.1472","article-title":"Dimethylmethylene blue based spectrophotometry of glycosaminogly cansinuntreated urine:arapidscreening procedure for mucopolysaccharidoses","volume":"35","author":"de Jong","year":"1989","journal-title":"Clin Chem"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/FTD.0b013e31826051bb","article-title":"Predictive performance of a busulfan pharmacokinetic model in children and young adults","volume":"34","author":"Bartelink","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.bbmt.2016.12.628","article-title":"Alternative donor transplantation with high-dose posttransplantation cyclophosphamide for refractory severe aplastic anemia","volume":"23","author":"DeZern","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host-disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbmt.2015.02.011","article-title":"Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines","volume":"6","author":"Aldenhoven","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17474086.2017.1318054","article-title":"Posttransplant cyclophosphamide a promising anti-graft versus host disease prophylaxis: where do we stand?","volume":"10","author":"Mussetti","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1200\/JCO.2014.60.4777","article-title":"Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults","volume":"33","author":"Kasamon","year":"2015","journal-title":"J Clin Oncol"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.bbmt.2015.08.034","article-title":"Single agent post-transplantation cyclophosphamide as GVHD prophylaxis after HLA-matched related BMT for pediatric and young adult patients with hematologic malignancies","volume":"22","author":"Jacoby","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ymgmr.2017.05.010","article-title":"Early hematopoietic stem cell transplantation in a patient with severe mucopolysaccharidosis II: A 7 years follow-up","volume":"12","author":"Anneliese","year":"2017","journal-title":"Mol Genet Metab Rep"},{"key":"R22-20230918","first-page":"663","article-title":"Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host disease","volume":"35(4_suppl)","author":"Hurabielle","year":"2017","journal-title":"Dermatol"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/bmt.2015.258","article-title":"TCR\u03b1\u03b2 CD19 depletion in allogeneic haematopoietic stem cell transplantation performed for Hurler syndrome","volume":"51","author":"Mainardi","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jpeds.2008.11.005","article-title":"Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy","volume":"154","author":"Wynn","year":"2009","journal-title":"J Pediatr"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201808000-00024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:17:40Z","timestamp":1695010660000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201808000-00024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001157","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}